News Archive

Patients assigned to the treatment, omecamtiv mecarbil, experienced a statistically significant difference in a composite endpoint of time to cardiovascular death or time to first heart failure event.

By evaluating patient-reported and electronic health record data, the pragmatic clinical study adds important real-world evidence to inform clinical practice.

The DCRI has received $44 million in funding to examine whether three immune modulators help prevent overactive immune response in moderate or severe cases of COVID-19.

DCRI’s Manesh Patel, MD, presented the late-breaking science at TCT Connect 2020.

Adrian Hernandez, MD, MHS, weighed in via STAT News on the recent pauses of three clinical trials that are working to develop a COVID-19 vaccine.

The nationwide program aims to build innovative and sustainable solutions to expand test access and uptake in underserved and vulnerable communities.

The clinical study's home-based design combines on-site nursing visits and mobile technology to embed research into patients' lives.

Building on DCRI’s strong history in building cardiovascular evidence, researchers at the Institute with a wide range of expertise are also considering how cardiovascular disease factors into other

EDITORS' NOTE: This story was updated January 19, 2021 when the study was published in Journal of the American Medical Association.

The IMPACT-AFib trial lays the groundwork for future large-scale trials to be conducted using electronic claims data.